{
    "clinical_study": {
        "@rank": "157962", 
        "arm_group": {
            "arm_group_label": "[18F]Florbetapir and PET imaging", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron\n      emission tomography (PET) for assessment of demyelination in the patients with relapsing\n      remitting multiple sclerosis."
        }, 
        "brief_title": "Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "The underlying goal of this study is to assess the feasibility of [18F]Florbetapir as an\n      imaging tool to detect demyelination in the brain of MS research participants and compare to\n      similarly aged healthy subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Eligibility criteria (for all subjects):\n\n          -  Ability to understand the purpose and risks of the study and provide signed and dated\n             informed consent and authorization to use protected health information in accordance\n             with national and local subject privacy regulations\n\n          -  Willingness to comply with study procedures\n\n          -  Willingness to provide written informed consent\n\n          -  Age greater than or equal to 18 and less than or equal to 60 years old at the time of\n             the informed consent\n\n          -  Subjects of childbearing potential must practice effective contraception during the\n             study and be willing and able to continue contraception until PET testing is\n             completed\n\n          -  For females, must be of non-childbearing potential or have a negative urine and blood\n             pregnancy test on the day of [18F]Florbetapir PET injection\n\n        Inclusion Criteria (Healthy Volunteers):\n\n          -  No history of or signs of acute or chronic neurological or psychiatric illness based\n             on evaluation by a research physician.\n\n        Inclusion Criteria (MS Subjects):\n\n          -  Have a diagnosis of relapsing remitting MS according to the 2010 MacDonald Criteria\n\n          -  Have at least 10 demyelinating lesion on brain MRI with the following\n             characteristics:\n\n          -  Hypointense on T2 weighted images with FLAIR\n\n        Exclusion Criteria (for all subjects):\n\n          -  The subject has clinically significant abnormal laboratory value and/or clinically\n             significant unstable medical or psychiatric illness\n\n          -  The subject has evidence of clinically significant gastrointestinal, cardiovascular,\n             hepatic, renal, hematological, neoplastic, endocrine, alternative neurological (other\n             than RRMS), immunodeficiency, pulmonary, or other disorder or disease.\n\n          -  Women who are pregnant or actively breastfeeding\n\n          -  The subject has any disorder that may interfere with drug absorption, distribution,\n             metabolism, or excretion (including gastrointestinal surgery)\n\n          -  The subject has participated in another clinical study within the previous 30 days\n\n          -  Renal impairment with a creatine clearance <80mL/minute at screening (creatine\n             clearance estimated by Cockcroft-Gault equation)\n\n          -  The subject is scheduled to have a major surgery or procedure during the time of the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767493", 
            "org_study_id": "Florbetapir MS 01"
        }, 
        "intervention": {
            "arm_group_label": "[18F]Florbetapir and PET imaging", 
            "description": "Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan", 
            "intervention_name": "[18F]Florbetapir and PET imaging", 
            "intervention_type": "Drug", 
            "other_name": "Amyvid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Multiple sclerosis", 
        "lastchanged_date": "June 5, 2013", 
        "link": {
            "description": "Institute for Neurodegenerative Disorders", 
            "url": "http://www.indd.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06510"
                }, 
                "name": "Institute for Neurodegenerative Disorders"
            }, 
            "investigator": {
                "last_name": "Danna Jennings, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis", 
        "overall_contact": {
            "last_name": "Barbara Fussell, RN", 
            "phone": "203-401-4300"
        }, 
        "overall_official": {
            "affiliation": "Institute for Neurodegenerative Disorders", 
            "last_name": "Danna Jennings, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the feasibility of [18F]Florbetapir PET as a biomarker for assessment of demyelination in MS subjects compared to healthy volunteers.", 
            "measure": "Feasibility of [18F]Florbetapir PET", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767493"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute for Neurodegenerative Disorders", 
            "investigator_full_name": "Danna Jennings, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Comparison of PET with MRI for demyelination in Multiple Sclerosis subjects", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Institute for Neurodegenerative Disorders", 
        "sponsors": {
            "collaborator": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Institute for Neurodegenerative Disorders", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}